Melanoma Clinical Trial

Clinical Study of Fianlimab in Combination With Cemiplimab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma

Summary

The primary objective of the study is to demonstrate superiority of fianlimab + cemiplimab compared to pembrolizumab, as measured by progression-free survival (PFS)

The secondary objectives of the study are:

To demonstrate superiority of fianlimab (REGN3767) + cemiplimab compared to pembrolizumab, as measured by overall survival (OS)
To demonstrate superiority in objective response rate (ORR) with fianlimab + cemiplimab compared to pembrolizumab
To characterize ORR, PFS, and OS with fianlimab + cemiplimab compared to cemiplimab to inform the contribution of each component
To assess immunogenicity of fianlimab and cemiplimab
To assess impact of fianlimab + cemiplimab on physical functioning and role functioning and global health status/quality of life, as compared to pembrolizumab in adults
To characterize safety and tolerability of treatment in patients 12 to <18 years of age
To characterize ORR, PFS, and OS with treatment in patients 12 to <18 years of age
To assess the safety and tolerability of fianlimab + cemiplimab compared to pembrolizumab and to cemiplimab
To characterize pharmacokinetics (PK) of fianlimab and cemiplimab using sparse PK sampling in patients aged ≥12 years

View Eligibility Criteria

Eligibility Criteria

Key Inclusion Criteria:

Age ≥12 years on the date of providing informed consent

Patients with histologically confirmed unresectable Stage III and Stage IV (metastatic) melanoma (AJCC, 8th revised edition) who have not received prior systemic therapy for advanced unresectable disease

Patients who received adjuvant and/or neoadjuvant systemic therapies are eligible if they did not have evidence of progression or recurrence of disease and/or discontinued due to occurrence of unmanageable irAEs ≥ grade 3 (with the exclusion of endocrinopathies which are fully controlled by hormone replacement) while on such therapies. Also, patients must have had a treatment-free and disease-free interval of >6 months.
Patients with acral and mucosal melanomas are eligible. Accrual will be limited to 10% of the total population.

Measurable disease per RECIST v1.1

Previously irradiated lesions can only be counted as target lesions if they have been demonstrated to progress and no other target lesion is available
Cutaneous lesions should be evaluated as non-target lesions

Performance status:

For adult patients: Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1
For pediatric patients: Karnofsky performance status ≥70 (patients ≥16 years) or Lansky performance status ≥70 (patients ≤16 years)
Anticipated life expectancy of at least 3 months

Key Exclusion Criteria:

Uveal melanoma
Ongoing or recent (within 2 years) evidence of an autoimmune disease that required systemic treatment with immunosuppressive agents. The following are non-exclusionary: vitiligo, childhood asthma that has resolved, residual hypothyroidism that requires only hormone replacement, psoriasis not requiring systemic treatment.
Uncontrolled infection with human immunodeficiency virus (HIV), hepatitis B (HBV) or hepatitis C virus (HCV) infection; or diagnosis of immunodeficiency that is related to, or results in chronic infection
Unknown BRAF V600 mutation status as described in the protocol

Systemic immune suppression:

Use of immunosuppressive doses of corticosteroids (≤10mg of prednisone per day or equivalent) within 14 days of the first dose of study medication. Physiologic replacement doses are allowed up to and including 10mg of prednisone/day or equivalent. Inhaled or topical steroids are permitted, if they are not for treatment of an autoimmune disorder.
Other clinically relevant forms of systemic immune suppression
Treatment with other anti-cancer therapy including immuno- therapy, chemotherapy, major surgery or biological therapy within 21 days prior to the first dose of trial treatment. Adjuvant hormonotherapy used for breast cancer or other hormone-sensitive cancers in long term remission is allowed.
History or current evidence of significant (CTCAE Grade ≥2) local or systemic infection (e. g., cellulitis, pneumonia, septicemia) requiring systemic antibiotic treatment within 14 days prior to the first dose of trial medication.

Active or untreated brain metastases or spinal cord compression. Patients with leptomeningeal disease are excluded. Patients with known brain metastases are eligible if they:

Received radiotherapy or another appropriate standard therapy for the brain metastases,
Have neurologically returned to baseline (except for residual signs and symptoms related to the CNS treatment) for at least 14 days prior to enrollment
Did not require immunosuppressive doses of corticosteroids therapy (>10mg of prednisone per day or equivalent) in the 14 days prior to enrollment
Are asymptomatic with a single untreated brain metastasis <10 mm in size

Note: Other protocol-defined Inclusion/ Exclusion criteria apply

Study is for people with:

Melanoma

Phase:

Phase 3

Estimated Enrollment:

1590

Study ID:

NCT05352672

Recruitment Status:

Recruiting

Sponsor:

Regeneron Pharmaceuticals

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 13 Locations for this study

See Locations Near You

The Angeles Clinic and Research Institute
Los Angeles California, 90025, United States More Info
Contact
310-496-0679
Orlando Health, Inc
Orlando Florida, 32806, United States More Info
Contact
321-841-9821
University of Tennessee Medical Center
Knoxville Tennessee, 37920, United States More Info
Contact
865-305-4893
Icon Cancer Centre Hobart
Hobart , 7000, Australia More Info
Contact
362402600
LTD High Technology Hospital Medcenter
Batumi , 6000, Georgia More Info
Contact
568999559
LTD New Hospitals
Tbilisi , 0114, Georgia More Info
Contact
95599373303
LTD Tbilisi State Medical University and Ingorokva High Medical Technology University Clinic
Tbilisi , 0144, Georgia More Info
Contact
851667553
TIM -Tbilisi Institute of Medicine
Tbilisi , 0160, Georgia More Info
Contact
995 595959570
Medulla - Clinics And Medical Centers
Tbilisi , 0168, Georgia More Info
LLC Todua Clinic
Tbilisi , 112, Georgia More Info
St. Vincents University Hospital
Dublin 4 , D04 T, Ireland More Info
Hospital Universitario Virgen de las Nieves
Granada , 18014, Spain More Info
Contact
34 958020000
Centro Integral Oncologico HM Clara Campal
Madrid , 28050, Spain

How clear is this clinincal trial information?

Study is for people with:

Melanoma

Phase:

Phase 3

Estimated Enrollment:

1590

Study ID:

NCT05352672

Recruitment Status:

Recruiting

Sponsor:


Regeneron Pharmaceuticals

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.